Healthcare / BiotechnologyASX
$0.36
-0.02 (-5.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-2.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$108M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-188.6%
↓Gross Margin
100.0%
↑Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-252.9%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.3M · net income $-2.9M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3M | $1.3M | $11065.00 | — | — |
| Net Income | $-2.9M | $-2.9M | $-2.8M | $-2.6M | $-2.1M |
| EBITDA | $-2.8M | $-2.8M | $-2.8M | $-2.8M | $-2.1M |
| EPS | -0.03 | -0.03 | -0.03 | -0.03 | — |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -229.6% | -229.6% | -26182.3% | — | — |
| Net Margin | -228.9% | -228.9% | -25580.2% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | — | — | — |
| Current Ratio | 8.40 | 8.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $-2.7M | $-1.9M | $-938236.00 |
| Returns | |||||
| ROE | -188.6% | -188.6% | -158.5% | -60.4% | -33.2% |
| Valuation | |||||
| P/B | 21.70 | 21.70 | 5.88 | 2.72 | 3.82 |
| Growth & Yield | |||||
| Revenue Growth | 11211.1% | 11211.1% | — | — | — |
| EPS Growth | 1.9% | 1.9% | -8.1% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.03
Residual
+78.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.